Needham & Company Cuts Target on Vivus (VVUS), Adjusts Qsymia Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Not Expecting E.U. Approval for Vivus' (VVUS) Qsiva, Could be a Plus for Orexigen (OREX) - Analyst
September 21, 2012 12:19 PM EDTShares Vivus (NASDAQ: VVUS) are getting slapped 11 percent Friday following news that the company expects EU regulators to recommending against... More
VIVUS (VVUS) Says EMA CHMP May Recommend Against MAA for Qsiva
September 21, 2012 7:05 AM EDTVIVUS, Inc. (Nasdaq: VVUS) announced that based on preliminary feedback from the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP), the company expects an opinion recommending against approval of the Marketing Authorization Application (MAA) for Qsiva (phentermine/topiramate ER) for the treatment of obesity.... More
